Skip to main content
      Conaghan et al. LEVI-04, neurotrophin-3 inhibitor in knee OA. 518 patients. Significant improvements in WOMAC pain and f

      Richard Conway RichardPAConway

      4 months 4 weeks ago
      Conaghan et al. LEVI-04, neurotrophin-3 inhibitor in knee OA. 518 patients. Significant improvements in WOMAC pain and function, and PGA. So sign of any increase in rapidly progressive OA (as with NGF inhibitors) @RheumNow #ACR24 Abstr#L15 https://t.co/qud4wTAikY https://t.co/0wjjG4U4bf
      Late breaking abstract L16
      Dapirolizumab Pegol showed significant improvement in SLE disease activity in our Phase 3 tri

      Antoni Chan MD (Prof) synovialjoints

      4 months 4 weeks ago
      Late breaking abstract L16 Dapirolizumab Pegol showed significant improvement in SLE disease activity in our Phase 3 trial. Key findings: - 49.5% of patients achieved BICLA response at Week 48 vs 34.6% on placebo (p=0.0110). - 60.1% achieved SRI-4 response vs 41.1% on placebo… https://t.co/ZawdsLOxmK https://t.co/gpV3KayIW1
      PHOENYCS GO, RCT of dapirplizumab, novel CD40Li in SLE

      Met primary endpoint (NNT~6 for BICLA) & numerical improve

      Mike Putman EBRheum

      4 months 4 weeks ago
      PHOENYCS GO, RCT of dapirplizumab, novel CD40Li in SLE Met primary endpoint (NNT~6 for BICLA) & numerical improvements in many other endpts 1 MI & 1 death from infection over 213 pts Encouraging for sure! Second phase 3 being launched #ACR24 @RheumNow Abstr#L16 #ACRbest https://t.co/QwDMKjhFvb
      RheumNow’s expanded coverage of the #ACR24 Annual meeting is sponsored in part by Novartis. All content is chosen by

      Dr. John Cush RheumNow

      4 months 4 weeks ago
      RheumNow’s expanded coverage of the #ACR24 Annual meeting is sponsored in part by Novartis. All content is chosen by RheumNow & its faculty
      In order to have a
      #DMOAD in knee #osteoarthritis

      ➡️ early detection may be v important

      Study of early pt Sympto

      Janet Pope Janetbirdope

      4 months 4 weeks ago
      In order to have a #DMOAD in knee #osteoarthritis ➡️ early detection may be v important Study of early pt Symptoms was done 2/3 had pain 1/2 #joint Swelling Need biomarkers & sensitive imaging in early #OA as symptoms are NOT uniform #ACR24 @RheumNow @ACRheum abst2111 https://t.co/K94m9rOjtP
      Pts w #osteoarthritis and T2 DM
      👇
      Who Have
      ⬆️pain
      Have
      worse control of #diabetes
      Even after adjusting for #

      Janet Pope Janetbirdope

      4 months 4 weeks ago
      Pts w #osteoarthritis and T2 DM 👇 Who Have ⬆️pain Have worse control of #diabetes Even after adjusting for #BMI Chicken or egg - which comes 1st 🤷‍♀️ #ACR24 @RheumNow @ACRheum Abst#2110 https://t.co/eN2xAw0EMG
      Does #hand #osteoarthritis
      Benefit from
      #traction #splinting?
      Nope 👎

      Small 2 site #RCT - not helpful

      I may Recom

      Janet Pope Janetbirdope

      4 months 4 weeks ago
      Does #hand #osteoarthritis Benefit from #traction #splinting? Nope 👎 Small 2 site #RCT - not helpful I may Recommend #splinting - sometimes pts get Pain relief - in my opinion but this one didn’t help #ACR24 @RheumNow @ACRheum Abst#2108 https://t.co/K0Ud7uCb1P
      How long is a long acting #intra-articular #steroid #injection in #knee #osteoarthritis?

      #IA steroids can be q3monthly

      Janet Pope Janetbirdope

      4 months 4 weeks ago
      How long is a long acting #intra-articular #steroid #injection in #knee #osteoarthritis? #IA steroids can be q3monthly #RCT of IA #fluticasone #propionate Was superior to #placebo Seemed to last approx 24 weeks ➡️ sub analysis in moderate pain, BMI<30 #ACR24 @RheumNow #2106 https://t.co/QBFCqXd1Q8
      #Scleroderma #molecular #signatures in #skin predict long term outcomes

      👇worst with inflammatory signature

      This m

      Janet Pope Janetbirdope

      4 months 4 weeks ago
      #Scleroderma #molecular #signatures in #skin predict long term outcomes 👇worst with inflammatory signature This may have clinical and trial applicability Nice work! Abst0711 #ACR24 @RheumNow @ACRheum https://t.co/3CFxu6bACu
      #PAH in #SSc still has a poor #prognosis
      👎
      Esp #ILD with PAH - a double whammy

      But also
      group 1 PAH
      And
      Some are

      Janet Pope Janetbirdope

      4 months 4 weeks ago
      #PAH in #SSc still has a poor #prognosis 👎 Esp #ILD with PAH - a double whammy But also group 1 PAH And Some are unclassifiable ▶️also bad px Need Earlier detection More interventions ?prevention Abst#0678 #ACR24 @RheumNow @ACRheum @sclerodermaUM https://t.co/AEQsTC1pzQ
      #Positive #RCT of #Nipocalimab a FcRn receptor inhibitor in #Sjogrens #Disease

      👏Phase 2 +RCT

      ESSSDAI and ESPRI both

      Janet Pope Janetbirdope

      4 months 4 weeks ago
      #Positive #RCT of #Nipocalimab a FcRn receptor inhibitor in #Sjogrens #Disease 👏Phase 2 +RCT ESSSDAI and ESPRI both improved 🤷‍♀️what it means to lower #antibodoes #Ro #La Excited for Phase 3 results #ACRBest #ACR24 @RheumNow @ACRheum abst#2527 https://t.co/NeeYT7VR16
      #MDA5 #dermatomyositis assoc #ILD

      May do better w
      #tofacitinib vs #CNI in 515 pts

      Too bad they didn’t do a pragmati

      Janet Pope Janetbirdope

      4 months 4 weeks ago
      #MDA5 #dermatomyositis assoc #ILD May do better w #tofacitinib vs #CNI in 515 pts Too bad they didn’t do a pragmatic RCT as we do t know the reasons for prescribing each #Rx But impressive survival w #tofa #ACR24 @ACRheum @RheumNow abst1736 https://t.co/HLJknSYcNJ
      ×